August 30, 2016 2:41 PM ET

Biotechnology

Company Overview of 3-V Biosciences, Inc.

Key Executives for 3-V Biosciences, Inc.

NameBoard RelationshipsTitleAge
Merdad V. Parsey M.D., Ph.D.12 RelationshipsChief Executive Officer, President and Director--
Urs Greber Ph.D.No RelationshipsCo-Founder--
David M. Mott NEA188 RelationshipsExecutive Chairman51
Lucas Pelkmans Ph.D.No RelationshipsCo-Founder--
Rekha Hemrajani No RelationshipsChief Financial Officer and Senior Vice President of Business & Financial Operations--
View More Key Executives

3-V Biosciences, Inc. Board Members*

NameBoard RelationshipsPrimary CompanyAge
David M. Mott NEA 188 RelationshipsMersana Therapeutics, Inc.51
Merdad V. Parsey M.D., Ph.D. 12 Relationships3-V Biosciences, Inc.--
Ed Harlow Jr., Ph.D. 12 Relationships3-V Biosciences, Inc.--
Robert J. Garland M.D. 44 RelationshipsNew Enterprise Associates--
Joseph D. Puglisi Ph.D. 25 RelationshipsPTC Therapeutics, Inc.--
View All Board Members

3-V Biosciences, Inc. Executive Committees*

Committee NameChairpersonBoard RelationshipsMembers
Advisory Board Jr., Ph.D.Ed Harlow12 Relationships6 Executives
View Committee Details
*Data is at least as current as the most recent Definitive Proxy.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

CEO COMPENSATION IN THIS INDUSTRY

  Industry Range
Salary
380.3K
Bonus
264.6K
Total Short Term Compensation
478.0K
Total Value of Options
33.9M
Compensation as of Fiscal Year
3-V Biosciences, Inc. CEO Compensation
Industry Average

INDUSTRY EXECUTIVE CHANGES

Bone Therapeutics SA Appoints Benoît Champluvier as Chief Technology and Manufacturing Officer
August 30, 2016 5:00 AM ET
Adverum Biotechnologies, Inc. Announces Resignation of John P. McLaughlin as Member of the Board of Directors, Chairman and Member of the Audit Committee and Member of the Compensation and Nominating and Corporate Governance Committees of the Board, Effective as of August 31, 2016
August 29, 2016 8:44 PM ET
OncoCyte Corporation Announces Board Changes
August 29, 2016 8:15 PM ET
Leap Therapeutics, Inc. and Macrocure Ltd. Announce Management Changes
August 29, 2016 12:51 PM ET
FORMA Therapeutics, Inc. Appoints Karoline Shair as Vice President, Legal and Chief Intellectual Property Counsel
August 29, 2016 12:00 PM ET

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact 3-V Biosciences, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.